Company / Shareholders' Equity
GT Biopharma, Inc. Shareholders' Equity History
FY2011-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$19.3M
FY2020
5-year range
-$61.8M / $251.7M
FY2016-FY2020
Trend
-107.7%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
GT Biopharma, Inc. reports negative total equity of -$19M in FY2020. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$19M in FY2020.
Improved from -$62M to -$19M over the past 4 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2020, shareholders' equity decreased 107.7% year-over-year.
- Peak shareholders' equity was recorded in FY2017.
- Lowest shareholders' equity in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | -$19.3M | -107.7% |
| FY2017 | $251.7M | +507.0% |
| FY2016 | -$61.8M | -109.1% |
| FY2015 | -$29.6M | +0.0% |
| FY2014 | -$29.6M | -366.9% |
| FY2013 | -$6.3M | +0.0% |
| FY2012 | -$6.3M | -24.2% |
| FY2011 | -$5.1M | - |
As of FY2020 · SEC 10-K · Updated Jun 24, 2026